Clinical Trials Directory

Trials / Conditions / FLT3-ITD Mutation

FLT3-ITD Mutation

8 registered clinical trials studyying FLT3-ITD Mutation — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingMRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
NCT07463651
The First Affiliated Hospital of Soochow UniversityPhase 3
UnknownCombination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML
NCT03642236
Nanfang Hospital, Southern Medical UniversityPhase 2 / Phase 3
UnknownItalian Non-Interventional Study of FLT3 Mutated AML Patients
NCT03547258
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS—
UnknownCombination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
NCT03135054
The University of Hong KongPhase 2
CompletedCombination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying
NCT03170895
The University of Hong KongPhase 2
UnknownSorafenib to Treat FLT3-ITD AML
NCT02156297
The First Affiliated Hospital of Soochow University—
CompletedUsing Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD
NCT03622541
The University of Hong KongPhase 2
AvailableIndividual Patient Compassionate Use of Crenolanib
NCT03620318
Arog Pharmaceuticals, Inc.—